Similar articles

• The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.

  Wolf JM, Rybicki LA, Lashner BA. Wolf JM, et al. Aliment Pharmacol Ther. 2005 Nov 1;22(9):783-8. doi: 10.1111/j.1365-2036.2005.02650.x. Aliment Pharmacol Ther. 2005. PMID: 16225486
• Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.

  Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Pardi DS, et al. Gastroenterology. 2003 Apr;124(4):889-93. doi: 10.1053/gast.2003.50156. Gastroenterology. 2003. PMID: 12671884 Clinical Trial.
• [Chronic inflammatory bowel diseases. Recurrence prevention = carcinoma prevention?].

  Vetter C. Vetter C. MMW Fortschr Med. 2005 Mar 31;147(13):10. MMW Fortschr Med. 2005. PMID: 15832752 German. No abstract available.
• [Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].

  Raskov HH. Raskov HH. Ugeskr Laeger. 2006 Jan 23;168(4):359-62. Ugeskr Laeger. 2006. PMID: 16436235 Review. Danish. No abstract available.
• Chemoprevention of colorectal cancer in ulcerative colitis.

  Croog VJ, Ullman TA, Itzkowitz SH. Croog VJ, et al. Int J Colorectal Dis. 2003 Sep;18(5):392-400. doi: 10.1007/s00384-002-0476-6. Epub 2003 Feb 6. Int J Colorectal Dis. 2003. PMID: 12904996 Review.